title: [Resistant hypercholesteremia in clinical practice: new insight into the causes and methods of treatment].
abstract: Coronary heart disease and other diseases caused by atherosclerosis, take first place among the causes of adult mortality. Leading role in the development of atherosclerosis belongs to violations of cholesterol metabolism. Reducing mortality from ischemic heart disease primarily associated with adequate correction of the lipid metabolism. The research of the possible causes and correction of resistant hypercholesterolemia is done. Determined that some patients with resistant to statins hypercholesteremia and normal or elevated levels of hormones T3 and T4 in the blood have isolated symptoms of hypothyroidism, which may be a manifestation of reducing tissue sensitivity to thyroid hormones. Adding to the statins levothyroxine in daily doses of 25-50 mkg have additional cholesterol reducing action, allowing to achieve target levels of lipoprotein in blood in patients. The use of levothyroxine in low doses in combination with statins is highly effective and economically justified.
authors.forename: A N
authors.initials: AN
authors.lastname: Kuchmin
authors.forename: S A
authors.initials: SA
authors.lastname: Chernov
authors.forename: A N
authors.initials: AN
authors.lastname: Teslia
authors.forename: D V
authors.initials: DV
authors.lastname: Cherkashin
authors.forename: K S
authors.initials: KS
authors.lastname: Shulenin
authors.forename: K B
authors.initials: KB
authors.lastname: Evsiukov
authors.forename: T V
authors.initials: TV
authors.lastname: Chursina
authors.forename: V I
authors.initials: VI
authors.lastname: Steklov
mesh_terms: D000328:Adult; D002318:Cardiovascular Diseases / Q000517:prevention & control; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D008055:Lipids / Q000097:blood; D008889:Military Personnel; D012720:Severity of Illness Index; D013963:Thyroid Hormones / Q000097:blood; D013974:Thyroxine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D013963:Thyroid Hormones; D013974:Thyroxine